PONS - Pioneering the Next Generation of Imaging Biomarkers

Cancer screening has made great strides, yet significant fractions are still detected at late stages when outcomes are poorer. A key limitation is that conventional imaging modalities lack the resolution and analytical sensitivity needed to discern the earliest visual indicators of carcinogenesis and progression. PONS is breaking these boundaries.

Our patented AI software enhances standard ultrasound scanners to provide unprecedented image clarity surpassing human vision. Now signs of tumors and lesions are visualized for breast, liver, ovarian, and other cancers where ultrasound is routinely used. By amplifying the power of existing devices with deep learning, we enable earlier diagnosis when intervention is most effective.

However, the implications extend far beyond screening. PONS unlocks vital new ultrasound data never before accessible. Patients can self-scan at home using smart guidance and transmit images for cloud analysis. For the first time, continuous disease progression data can be captured outside hospital settings - detecting how tumors are responding to therapy and if new risks emerge. This has the potential to transform drug trials.

Consider how PONS could elevate ultrasound from episodic scans to an essential imaging biomarker:

• Patients self-scan weekly revealing treatment responses

• Data feeds advanced tissue characterization algorithms

• Longitudinal analytics quantify patient-specific trajectories

• New signals identify efficacy, resistance, and side effects

By gathering frequent high-resolution data anywhere, PONS can power decentralized trials embedded into normal care routines. Ultimately this means achieving precision therapy guided by an individual's unique markers.

The future of not just ultrasound but medical imaging will be defined by intelligence extraction - going far beyond just static pictures toward deep phenotyping. With our rapidly growing dataset and continued algorithm innovations, PONS aims to spearhead the next generation of imaging biomarkers propelling preventative early detection while reshaping therapeutic development. Our software unlocks undiscovered potential in existing devices to fundamentally elevate screening and personalization.